RESUMEN
A novel series of 2,5-dihydropyrazolo[4,3-c]quinolin-3-ones has been prepared. These compounds showed good PDE 4 inhibitory activity and weak affinity for rolipram's binding site. They also exhibited a good anti-inflammatory profile without emetic side effects.
Asunto(s)
Inhibidores de Fosfodiesterasa/síntesis química , Quinolonas/síntesis química , Quinolonas/farmacología , Animales , Antiasmáticos/síntesis química , Antiasmáticos/química , Antiasmáticos/farmacología , Eméticos/síntesis química , Eméticos/química , Eméticos/farmacología , Cobayas , Técnicas In Vitro , Modelos Moleculares , Inhibidores de Fosfodiesterasa/química , Inhibidores de Fosfodiesterasa/farmacología , Quinolonas/química , Relación Estructura-ActividadRESUMEN
The synthesis of a new family of benzyl derivatives of 2,1,3-benzo- and benzothieno[3,2-a]thiadiazine 2,2-dioxides was achieved. The biological data revealed the first heterocyclic family of compounds with PDE 7 inhibitory properties appearing to be a new objective for the treatment of T-cell-dependent disorders. The IC(50) values or percent inhibition values of the compounds against PDE 7 were calculated by testing them against human recombinant PDE 7 expressed in S. cerevisiae. In this expression system the only cyclic nucleotide hydrolyzing activity present in cell extracts corresponded to human PDE 7. Isoenzyme selectivity PDE 7 versus PDE 4 and PDE 3 was also measured. Considering simultaneously inhibition of the three different isoenzymes, monobenzyl derivatives 15 and 23 showed interesting PDE 7 potency (around 10 microM); although not statistically significant, a trend toward selectivity with respect to PDE 3 and PDE 4 was obtained. Benzothiadiazine 16, although less potent at PDE 7 (IC(50) = 25 microM), also showed a trend of selectivity toward PDE 3 and PDE 4. These compounds are considered the best leads for further optimization.
Asunto(s)
3',5'-AMP Cíclico Fosfodiesterasas/antagonistas & inhibidores , Benzotiadiazinas/síntesis química , Inhibidores Enzimáticos/síntesis química , Isoenzimas/antagonistas & inhibidores , Tiadiazinas/síntesis química , Benzotiadiazinas/química , Benzotiadiazinas/farmacología , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 4 , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 7 , Evaluación Preclínica de Medicamentos , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Humanos , Proteínas Recombinantes/antagonistas & inhibidores , Saccharomyces cerevisiae/efectos de los fármacos , Saccharomyces cerevisiae/enzimología , Relación Estructura-Actividad , Tiadiazinas/química , Tiadiazinas/farmacologíaRESUMEN
A series of 3,4-diaryloxazolones were prepared and evaluated for their ability to inhibit cyclooxygenase-2 (COX-2). Extensive structure-activity relationship work was carried out within this series, and a number of potent and selective COX-2 inhibitors were identified. The replacement of the methyl sulfone group on the 4-phenyl ring by a sulfonamide moiety resulted in compounds with superior in vivo antiinflammatory properties. In the sulfonamide series, the introduction of a methyl group at the 5-position of the oxazolone ring gave rise to very COX-2-selective compounds but with decreased in vivo activity. Selected 3,4-diaryloxazolones exhibited excellent activities in experimental models of arthritis and hyperalgesia. The in vivo activity of these compounds was confirmed with the evaluation of their antipyretic effectiveness and their ability to inhibit migration of proinflammatory cells. As expected from their COX-2 selectivity, most of the active compounds lacked gastrointestinal toxicity in vivo in rats after a 4-day treatment of 100 mg/kg/day. Within this novel series, sulfonamides 9-11 have been selected for further preclinical evaluation.
Asunto(s)
Inhibidores de la Ciclooxigenasa/síntesis química , Inhibidores de la Ciclooxigenasa/farmacología , Oxazoles/síntesis química , Oxazoles/farmacología , Animales , Antiinflamatorios no Esteroideos/síntesis química , Antiinflamatorios no Esteroideos/farmacología , Antiinflamatorios no Esteroideos/uso terapéutico , Artritis Experimental/tratamiento farmacológico , Inhibidores de la Ciclooxigenasa/uso terapéutico , Fiebre/tratamiento farmacológico , Humanos , Espectroscopía de Resonancia Magnética , Masculino , Oxazoles/uso terapéutico , Prostaglandina-Endoperóxido Sintasas/sangre , Ratas , Ratas Wistar , Relación Estructura-ActividadRESUMEN
OBJECTIVE: Ebastine and terfenadine are both marketed nonsedating H1 histamine receptor antagonists. Although apparently similar in chemical structure, the compounds have different pharmacological profiles, particularly with respect to cardiac effects. These effects are consistently observed in a wide range of experimental models with terfenadine, but not with ebastine, despite the fact that the latter is more potent as an antihistamine. The objective of this study was to provide a structural basis to explain such differences. DESIGN: A complete computer-assisted conformational and electronic characterisation was made for both drugs. RESULTS: The preferred 3-dimensional spatial orientations were found to be different, as were the molecular locations of the highest occupied and lowest unoccupied molecular orbitals. Furthermore, for terfenadine, additional points of interaction as a hydrogen bond donor were found, which were not evident in ebastine or other noncardiotoxic antihistamines. These extra points of interaction were also found in other compounds that have shown cardiac effects similar to those of terfenadine.
Asunto(s)
Butirofenonas/química , Antagonistas de los Receptores Histamínicos H1/química , Piperidinas/química , Terfenadina/química , Modelos Moleculares , Conformación Molecular , Procesamiento de Señales Asistido por ComputadorRESUMEN
In this report, a novel inhibitor of farnesyl protein transferase (FPTase) is described. The compound, XR3054, is structurally similar to farnesol, a component of the reaction in which FPTase catalyses transfer of farnesol pyrophosphate to the CAAX recognition motif on proteins. The compound was selected initially because of its ability to inhibit in vitro farnesylation of CAAX recognition peptides with an IC50 of 50 microM. The farnesylation of p21 ras was reduced in a dose-dependent manner in the presence of XR3054. Similarly XR3054 was able to reduce the anchorage-independent growth of V12 H-ras transformed NIH 3T3 cells in a focus formation assay in soft agar, with an IC50 value of 30 microM, whilst not affecting the anchorage-independent growth of v-raf transformed cells. XR3054 reduced the phosphorylation of p42 mitogen activated protein (MAP) kinase in parental NIH 3T3 cells and V12 H-ras transformed NIH 3T3 cells, but constitutively active v-raf transformed cells showed no reduction in phosphorylation of ERK2 in the presence of XR3054. XR3054 inhibited the proliferation of the prostatic cancer cell lines LnCAP and PC3 and the colon carcinoma SW480 and HT1080 (IC50 values of 12.4, 12.2, 21.4 and 8.8 microM, respectively) but was relatively inactive when tested against a panel of breast carcinoma cell lines. The activity did not relate to the presence of mutant or wild-type ras in the cell lines tested. In conclusion XR3054 inhibits ras farnesylation, MAP kinase activation and anchorage-independent growth in NIH 3T3 transformed with v12 H-ras. Since the antiproliferative effect of the compound is not related to the ras phenotype, XR3054 may also have effects on other cell signalling mechanisms.
Asunto(s)
Transferasas Alquil y Aril/antagonistas & inhibidores , Terpenos/farmacología , División Celular/efectos de los fármacos , Ciclohexenos , Genes ras/efectos de los fármacos , Humanos , Limoneno , Prenilación de Proteína/efectos de los fármacos , Células Tumorales CultivadasRESUMEN
The cutaneous lymphocyte-associated antigen defines T lymphocytes with cutaneous tropism under inflammatory conditions. Bacterial infections participate in cutaneous inflammations, such as atopic dermatitis or psoriasis. Bacterial superantigens, such as staphylococcal enterotoxin B, can activate peripheral blood mononuclear cells to induce effector T cells bearing the T cell skin homing receptor cutaneous lymphocyte-associated antigen via enhancement of interleukin-12 production. We have identified and characterized the anti-inflammatory effects of different phosphodiesterase inhibitors on this system. Our data indicate that the selective type 4 phosphodiesterase inhibitor rolipram inhibits the Staphylococcal enterotoxin B-mediated generation of cutaneous lymphocyte-associated antigen positive CD3+ cells from peripheral blood mononuclear cells by reducing interleukin-12 production in a concentration-dependent manner. Conversely, type 3 phosphodiesterase or type 5 phosphodiesterase selective inhibitors were not effective. The rolipram inhibitory effect was on interleukin-12 production, as exogenously added interleukin-12 could revert rolipram suppression. These results suggest that selective type 4 phosphodiesterase inhibition may have beneficial effects on T cell mediated skin inflammatory processes characterized by the presence of bacterial infections, that are thought to exacerbate ongoing skin inflammation.
Asunto(s)
Enterotoxinas/farmacología , Inhibidores de Fosfodiesterasa/farmacología , Pirrolidinonas/farmacología , Receptores Mensajeros de Linfocitos/metabolismo , Piel/efectos de los fármacos , Linfocitos T/efectos de los fármacos , Animales , Antígenos de Diferenciación de Linfocitos T , Antígenos de Neoplasias , Bucladesina/farmacología , Complejo CD3/efectos de los fármacos , Complejo CD3/metabolismo , AMP Cíclico/metabolismo , Dinoprostona/farmacología , Relación Dosis-Respuesta a Droga , Citometría de Flujo , Humanos , Interleucina-12/biosíntesis , Interleucina-12/farmacología , Activación de Linfocitos , Glicoproteínas de Membrana/efectos de los fármacos , Glicoproteínas de Membrana/metabolismo , Ratones , Ratas , Rolipram , Piel/citología , Piel/metabolismo , Linfocitos T/inmunología , Linfocitos T/metabolismoRESUMEN
Overexpression of P-glycoprotein (P-gp) is a potential cause of multidrug resistance (MDR) in tumours. We have previously reported that XR9051 (N-(4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydro-2-isoquinolyl)ethyl)phe nyl)-3-((3Z,6Z)-6-benzylidene-1-methyl-2,5-dioxo-3-pipera zinylidene)methylbenzamide) is a potent and specific inhibitor of P-gp, which reverses drug resistance in several murine and human MDR cell lines. In this study we have evaluated the in vivo efficacy of this novel modulator in a panel of murine and human tumour models and examined its pharmacokinetic profile. Efficacy studies in mice bearing MDR syngeneic tumours (P388/DX Johnson, MC26) or human tumour xenografts (A2780AD, CH1/DOXr, H69/LX) demonstrated that co-administration of XR9051 significantly potentiated the anti-tumour activity of a range of cytotoxic drugs. This modulatory activity was observed following parenteral and oral co-administration of XR9051. In addition, the combination schedules were well-tolerated. Following intravenous administration in mice, XR9051 is rapidly distributed and accumulates in tumours and other tissues. In addition, the compound is well-absorbed after oral administration. These data suggest that XR9051 has the potential for reversing clinical MDR mediated by P-glycoprotien.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/fisiología , Compuestos de Bencilideno/farmacología , Resistencia a Múltiples Medicamentos , Isoquinolinas/farmacología , Tetrahidroisoquinolinas , Animales , Compuestos de Bencilideno/farmacocinética , Neoplasias del Colon/tratamiento farmacológico , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Absorción Intestinal , Isoquinolinas/farmacocinética , Leucemia Experimental/tratamiento farmacológico , Ratones , Trasplante HeterólogoRESUMEN
We have synthesised and evaluated a series of anthranilamide based modulators of P-glycoprotein. These studies have identified XR9576(2), a potent inhibitor of P-glycoprotein in vitro and in vivo. The general synthesis and the SAR of these compounds are described.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Resistencia a Múltiples Medicamentos , ortoaminobenzoatos/farmacología , Doxorrubicina/farmacología , Sinergismo Farmacológico , Humanos , Relación Estructura-Actividad , Células Tumorales Cultivadas , ortoaminobenzoatos/químicaRESUMEN
The synthesis of an azaspirocyclic analogue of FR901483, phosphate 2, is described based on the implementation of a key 5-endo aminocyclization promoted by iodine for direct functionalization of the 1-azaspiro[4.5]decane ring at the C-3 atom. Compound 2 has no inhibitory activity in the cell proliferation assays reported.
Asunto(s)
Inmunosupresores/síntesis química , Inmunosupresores/farmacología , Compuestos Organofosforados/síntesis química , Compuestos Organofosforados/farmacología , División Celular/efectos de los fármacos , Humanos , Inmunosupresores/química , Técnicas In Vitro , Linfocitos/citología , Linfocitos/efectos de los fármacos , Espectroscopía de Resonancia Magnética , Modelos Moleculares , Conformación Molecular , Compuestos Organofosforados/química , Relación Estructura-ActividadRESUMEN
A common pharmacophore for compounds structurally related to nitraquazone has been derived. Using this pharmacophore, new structures have been designed, synthesized, and evaluated for their inhibitory potencies against cyclic adenosine 5'-monophosphate (cAMP) specific phosphodiesterase (PDE 4). From these compounds, 4-benzylamino-2-butylthieno[3,2-d]pyrimidine (4) was selected for optimization. The effects of changes to the lipophilic groups and the amino linkage on the PDE 4 activity have been investigated. As a result, some potent PDE 4 inhibitors, selective with respect to PDE 3, have been identified. A selected group of compounds have been further evaluated for their ability to displace [3H]rolipram from its binding site and also to potentiate isoprenaline-induced cAMP accumulation in isolated guinea pig eosinophils. Of these, 2-butyl-4-cyclohexylaminothieno[3,2-d]pyrimidine (33) has an interesting profile, with an important improvement in PDE 4/[3H]rolipram ratio with respect to reference drugs, and good activity in cAMP potentiation, consistent with efficient cell penetration.
Asunto(s)
3',5'-AMP Cíclico Fosfodiesterasas/metabolismo , Antiasmáticos/síntesis química , Diseño de Fármacos , Inhibidores de Fosfodiesterasa/síntesis química , Pirimidinas/síntesis química , Tiofenos/síntesis química , Animales , Antiasmáticos/química , Antiasmáticos/metabolismo , Antiasmáticos/farmacología , Unión Competitiva , AMP Cíclico/metabolismo , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 3 , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 4 , Evaluación Preclínica de Medicamentos , Eosinófilos/efectos de los fármacos , Eosinófilos/metabolismo , Cobayas , Técnicas In Vitro , Masculino , Modelos Moleculares , Miocardio/enzimología , Inhibidores de Fosfodiesterasa/química , Inhibidores de Fosfodiesterasa/metabolismo , Inhibidores de Fosfodiesterasa/farmacología , Pirimidinas/química , Pirimidinas/metabolismo , Pirimidinas/farmacología , Pirrolidinonas/metabolismo , Rolipram , Relación Estructura-Actividad , Tiofenos/química , Tiofenos/metabolismo , Tiofenos/farmacologíaRESUMEN
XR9051 (N-(4-(2-(6,7-Dimethoxy-1,2,3,4-tetrahydro-2-isoquinolyl)ethyl)phe nyl)-3-((3Z,6Z)-6-benzylidene-1-methyl-2,5-dioxo-3-pipera zinylidene) methylbenzamide) was identified as a potent modulator of P-glycoprotein-mediated multidrug resistance (MDR) following a synthetic chemistry programme based on a natural product lead compound. The activity of XR9051 was determined using a panel of human and murine drug-resistant cell lines (H69/LX4, 2780AD, EMT6/AR 1.0, MC26 and P388/DX Johnson). XR9051 was able to reverse resistance to a variety of cytotoxic drugs, including doxorubicin, etoposide and vincristine, which are associated with classical MDR. At a concentration of 0.3-0.5 microM, XR9051 was able to fully sensitize resistant cells to cytotoxics, whereas little or no effect was observed on the corresponding parental cell lines. No effect of XR9051 was observed on the response of cells to non-MDR cytotoxics such as methotrexate and 5-fluorouracil. XR9051 was consistently more potent than cyclosporin A (CsA) and verapamil (Vpm) in all assays used. XR9051 inhibited the efflux of [3H]daunorubicin from preloaded cells and, unlike CsA and Vpm, remained active for several hours after removal of resistance-modifying agent. In photoaffinity labelling experiments employing [3H]azidopine, XR9051 was able to displace binding to P-glycoprotein. In binding studies using [3H]vinblastine, XR9051 was shown to be a potent inhibitor of the binding of the cytotoxic to P-glycoprotein (EC50 = 1.4 +/- 0.5 nM). Taken together, the results indicate that XR9051 reverses the MDR phenotype through direct interaction with P-glycoprotein.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Antibióticos Antineoplásicos/metabolismo , Resistencia a Múltiples Medicamentos , Piperazinas/metabolismo , Animales , Antineoplásicos Fitogénicos/metabolismo , Daunorrubicina/metabolismo , Doxorrubicina/metabolismo , Resistencia a Antineoplásicos , Humanos , Ratones , Etiquetas de Fotoafinidad , Factores de Tiempo , Células Tumorales Cultivadas/metabolismo , Vinblastina/metabolismoRESUMEN
A number of new 1,4-benzodiazepin-2-one-based gastrin/CCK-B receptor antagonists related to the archetypal analogue L-365,260, and more closely to the recently reported compound YM022, have been synthesized and evaluated for biological activity. The compounds were screened for their ability to inhibit the binding of [125I]CCK-8 to gastrin/CCK-B receptors prepared from rat brains and that of [3H]L-364,718 to CCK-A receptors from rat pancreas, and were shown to be potent and selective ligands for the gastrin/CCK-B receptor. Functional studies in vivo demonstrated the compounds to be antagonists of the receptor as evidenced by their ability to inhibit pentagastrin-induced gastric acid secretion in anesthetized rats. More extensive evaluation in vivo included determination of ED50 values in the rat acid secretion model for selected compounds and an examination of the effect of these compounds on pentagastrin-induced gastric acid secretion in Heidenhain pouch dogs following oral and intravenous administration. Two compounds, i.e. (3R)-N-[1-[(tert-butylcarbonyl)methyl]-2,3-dihydro-2-oxo-5-(2-pyri dyl) -1H-1,4-benzodiazepin-3-yl]-N'-[3-(methylamino)phenyl]urea, 15c (YF476), and (3R)-N-[1-[(tert-Butylcarbonyl)methyl]-2,3-dihydro-2-oxo-5- (2-pyridyl)-1H-1,4-benzodiazepin-3-yl]-N'-[3-(dimethylamino)phenyl ]urea hydrochloride, 15d, showed potent dose-dependent effects in both models with the former showing excellent oral bioavailability and an ED50 of 21nmol/kg po in dogs. 15c is currently under clinical investigation for the treatment of gastro-oesophagal reflux disease (GORD).
Asunto(s)
Benzodiazepinonas/farmacología , Antagonistas de Hormonas/farmacología , Compuestos de Fenilurea/farmacología , Receptores de Colecistoquinina/antagonistas & inhibidores , Administración Oral , Animales , Benzodiazepinas/farmacología , Benzodiazepinonas/síntesis química , Benzodiazepinonas/química , Benzodiazepinonas/metabolismo , Unión Competitiva , Encéfalo/metabolismo , Devazepida , Perros , Ácido Gástrico/metabolismo , Antagonistas de Hormonas/síntesis química , Estructura Molecular , Páncreas/metabolismo , Pentagastrina/farmacología , Compuestos de Fenilurea/síntesis química , Compuestos de Fenilurea/química , Unión Proteica , Ratas , Ratas Sprague-Dawley , Receptor de Colecistoquinina B , Receptores de Colecistoquinina/metabolismo , Sincalida/metabolismo , Relación Estructura-ActividadRESUMEN
A number of new technologies that enable high-throughput, cost-effective screening of potential drug candidates have been developed in recent years. Such compounds may be derived from the large proprietary collections held by pharmaceutical companies, from new synthetic approaches such as combinatorial chemistry, or from natural sources. The latter remain a major source of new chemicals: many are already used in human treatment and many others are currently undergoing evaluation as the potential medicines of the future.
Asunto(s)
Química Farmacéutica/métodos , Evaluación Preclínica de Medicamentos/métodos , Diseño Asistido por Computadora , Diseño de Fármacos , PéptidosRESUMEN
Much attention is currently focused on inhibitors of thrombin as potential anticoagulants. We have previously reported thrombin inhibitors based on fragments of fibrinogen containing a ketomethylene isostere at P1-P'1. We now expand on these early findings by reporting on tripeptide based inhibitors of thrombin containing arginine or lysine ketones at the C-terminus. A large variety of such ketones have been studied and compared in their ability to increase the thrombin time in human plasma. In the case of arginine or lysine ketones the order of activity (i.e. decreasing IC50 TT) was: alkyl ketones < beta-ketoesters < difluoro beta-ketoamides < alkyloxymethyl ketones < fluoroketones. Lysine analogues were generally found to be ca. ten-fold less active than their arginine counterparts. However, in the case of alpha-ketoesters the lysine derivatives were superior to all the types of arginine ketones studied (including the arginine alpha-keto ester derived thrombin inhibitor). A mechanistic explanation of the relative inactivity of the arginine alpha-keto ester derivative is proposed. All the highly electrophilic ketones were found to be slow-binding with thrombin.
Asunto(s)
Anticoagulantes/farmacología , Antitrombinas/farmacología , Arginina/análogos & derivados , Lisina/análogos & derivados , Trombina/antagonistas & inhibidores , Secuencia de Aminoácidos , Anticoagulantes/síntesis química , Antitrombinas/síntesis química , Antitrombinas/química , Arginina/química , Ésteres/síntesis química , Ésteres/química , Ésteres/farmacología , Humanos , Cetonas/síntesis química , Cetonas/química , Cetonas/farmacología , Lisina/química , Espectrometría de Masas , Modelos Químicos , Datos de Secuencia Molecular , Estructura Molecular , Oligopéptidos/síntesis química , Oligopéptidos/química , Oligopéptidos/farmacología , Trombina/metabolismo , Tiempo de TrombinaRESUMEN
OBJECTIVE: To investigate the relation between parental employment in the nuclear industry and childhood leukaemia and non-Hodgkin's lymphoma. DESIGN: Case-control study. SETTING-West Berkshire and Basingstoke and North Hampshire District Health Authorities. SUBJECTS: 54 children aged 0-4 years who had leukaemia or non-Hodgkin's lymphoma diagnosed during 1972-89, who were born in the study area and were resident there when cancer was diagnosed. Six controls were selected for each case: four from hospital delivery registers and two from livebirth registers maintained by the NHS central register. Controls were matched for sex, date of birth (within six months), and area of residence at birth and time of diagnosis. MAIN OUTCOME MEASURES: Parents' employment by the nuclear industry and exposure to ionising radiation at work. RESULTS: Five (9%) of the 54 cases and 14 (4%) of the 324 controls had fathers or mothers, or both, who had been employed by the nuclear industry (relative risk 2.2, 95% confidence interval 0.6 to 6.9). Nuclear industry employees who work in areas where exposure to radiation is possible are given film badges to monitor their exposure to external penetrating ionising radiation. Three fathers of cases and two fathers of controls (and no mothers of either) had been monitored in this way before their child was conceived (relative risk 9.0, 95% confidence interval 1.0 to 107.8). No father (of a case or control) had accumulated a recorded dose of more than 5 mSv before his child was conceived, and no father had been monitored at any time in the four years before his child was conceived. A dose-response relation was not evident among fathers who had been monitored. CONCLUSIONS: These results suggest that the children of fathers who had been monitored for exposure to external penetrating ionising radiation in the nuclear industry may be at increased risk of developing leukaemia before their fifth birthday. The finding is based on small numbers and could be due to chance. If the relationship is real the mechanisms are far from clear, except that the effect is unlikely to be due to external radiation; the possibility that it could be due to internal contamination by radioactive substances or some other exposure at work should be pursued. The above average rates of leukaemia in the study area cannot be accounted for by these findings.
Asunto(s)
Exposición a Riesgos Ambientales , Leucemia Inducida por Radiación/epidemiología , Leucemia/epidemiología , Linfoma no Hodgkin/epidemiología , Neoplasias Inducidas por Radiación/epidemiología , Reactores Nucleares , Padres , Estudios de Casos y Controles , Preescolar , Empleo , Inglaterra/epidemiología , Femenino , Humanos , Incidencia , Lactante , Leucemia/etiología , Leucemia Inducida por Radiación/etiología , Linfoma no Hodgkin/etiología , Masculino , Neoplasias Inducidas por Radiación/etiología , Factores de RiesgoRESUMEN
Flow cytometry is a technique which permits the characterisation of individual cells in populations, in terms of distributions in their properties such as DNA content, protein content, viability, enzyme activities and so on. We review the technique, and some of its recent applications to microbiological problems. It is concluded that cellular heterogeneity, in both batch and continuous axenic cultures, is far greater than is normally assumed. This has important implications for the quantitative analysis of microbial processes.
Asunto(s)
Bacterias/crecimiento & desarrollo , Recuento de Colonia Microbiana , Citometría de Flujo/métodos , Bacterias/metabolismo , ADN Bacteriano/análisis , Escherichia coli/crecimiento & desarrollo , Micrococcus luteus/crecimiento & desarrollo , ARN Bacteriano/análisisRESUMEN
The gastric acid inhibitory activities of a peptide-like gastrin receptor antagonist, Boc-beta Ala-Trp-Leu-Asp-O(CH2)2-Ph-4-F (CH-486), a nonpeptide gastrin/CCK-B antagonist (L-365,260), and a CCK-A antagonist (L-364,718), were investigated in the gastric lumen-perfused anaesthetized rat. A single i.v. injection of CH-486, 100 mumol/kg, reduced acid secretion stimulated by pentagastrin, 15 micrograms kg/h, to unstimulated levels, with no recovery within 50 min. Histamine-, 0.1 mumol kg/min, and carbamylcholine-, 0.1 mg kg/h, stimulated acid secretion were also reduced to unstimulated levels by CH-486, 100 mumol/kg, although with these latter two stimulants the inhibition was transient. L-365,260 and L-364,718, 10 mumol/kg, significantly inhibited both pentagastrin- and histamine-stimulated acid secretion, the latter again transiently. We conclude that the non-selective nature of the gastric acid inhibitory activity of gastrin antagonists might allow novel approaches to control gastric acid secretion in peptic ulcer disease.